About Us
Corporate overview
Our History & Milestones
Our Purpose
Our Leadership Team
Research & Development
ESG Footprint
— Overview
— Environment
— Social
— Corporate Governance
— Policies & Disclosures
Our ESG Footprint: ‘Caring for Society’
Learn More
Our History: ‘built on a foundation of strong values.
Learn More
Businesses
Business overview
Active Pharma Ingredients (API)
— Regulatory
Specialty Chemicals
API: ‘discover our API & Bulk Drugs Portfolio’
Learn More
Chemicals: ‘serving India through our Speciality Chemicals’
Learn More
Manufacturing
Manufacturing Capability
Accreditations
IBU Derivative: ‘going up the value chain’
Learn More
Ethyl Acetate: ‘Fostering Green Chemistry’
Learn More
Investors
Overview
Annual Reports
Annual Returns
Sustainability Report
Greenhouse Gas Emissions Report
Financial Performance
Subsidiaries Financial Statements
Shareholding Pattern
Governance Reports
Press Releases & News Publications
Shareholders Meetings AGM/EGM/Postal Ballot
Investors Education Protection Funds / Unclaimed Dividend
Corporate Policies
Corporate Benefits
Investor Services
Email Registration Form
KYC & Nomination Forms
Stock Information
Board of Directors
Governance Structure
Disclosure under Regulation
46
INVESTOR ZONE
— Investor Events
— Investor Resources
— Earnings Concall
— Analyst Speak
ESG Footprint
— Overview
— Environment
— Social
— Corporate Governance
— Policies & Disclosures
Media
Media Coverage
Press Releases & News Publications
Media Coverage
Learn More
Press Releases & News Publications
Learn More
Careers
Get In Touch
Media Coverage
Home
Media Coverage
2022
November 01 - November 03
Largest Ibuprofen API maker eyes double revenue in next four years
2022
May 17 - May 19
IOL to diversify its API and specialty chemicals portfolios to boost sales
ENGAGE WITH OUR TEAM NOW
